PTJ
GPCR icon

Paul Tudor Jones’s Structure Therapeutics GPCR Stock Holding History

Paul Tudor Jones’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88M Sell
53,656
-21,645
-29% -$958K ﹤0.01% 1680
2026
Q1 		$3.63M Buy
75,301
+40,248
+115% +$2.75M 0.01% 1404
2025
Q4 		$2.44M Buy
+35,053
New +$1.43M ﹤0.01% 1675

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Paul Tudor Jones's GPCR Position: Q2 2026 in Review

Paul Tudor Jones reduced its Structure Therapeutics (GPCR) stake by 29% in Q2 2026, selling an estimated $958K and leaving 53,656 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

Paul Tudor Jones first reported a position in GPCR in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.63M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Paul Tudor Jones held 53,656 shares of Structure Therapeutics worth $2.88M as of Q2 2026.
  • Paul Tudor Jones sold 21,645 Structure Therapeutics shares in Q2 2026, an estimated $958K.
  • Structure Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1680 holding.
  • Paul Tudor Jones first reported a position in Structure Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Paul Tudor Jones's Structure Therapeutics position peaked at $3.63M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.